Sp928
PRESENTATION OF ENDOSCOPY, TECHNOLOGY & IMAGING (ETI) SECTION RESEARCH MENTOR AWARD: VANESSA M. SHAMI, MD, AGAF, FASGE, FACG
Date
May 20, 2024
Tracks
Related Products
INCREASED REFLUX SECONDARY BILE ACIDS ARE ASSOCIATED WITH SHIFTS TO THE MICROBIOME AND TRANSCRIPTOME IN BARRETT’S ESOPHAGUS
Background: Bile acids comprise a major component of refluxate in GERD, the major risk factor for Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC). Bile acids are metabolized by bacteria, and bacterial composition is also impacted by exposure to bile acids…
DEVELOPMENT AND VALIDATION OF A MACHINE LEARNING (ML) BASED DECISION-MAKING TOOL TO DETERMINE RISK AND TIMING OF RECURRENCE OF BARRETT’S ESOPHAGUS (BE) NEOPLASIA AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY (EET)
Recent studies have described the durability of EET for BE-related neoplasia and the risk of neoplastic recurrence after achieving complete eradication of intestinal metaplasia (CE-IM). Current guidelines for endoscopic surveillance intervals post-EET are based on limited evidence…
AGA Adoption of Advanced Tissue Resection in the US
This clinical symposium will focus on the current state of the art for advanced tissue resection techniques (specifically ESD) and strategies for achieving the goal of reimbursement…
VALIDATION OF COPY NUMBER ABERRATION AND METHYLATED DNA MARKERS FOR DIFFERENTIATION OF NON-DYSPLASTIC BARRETT’S ESOPHAGUS FROM BARRETT’S ESOPHAGUS WITH HIGH GRADE DYSPLASIA AND ESOPHAGEAL ADENOCARCINOMA : A MULTICENTER STUDY
Endoscopic surveillance of Barrett’s esophagus (BE) is recommended to identify dysplasia (low grade [LGD], high grade [HGD]) or adenocarcinoma [EAC]) for endoscopic intervention. However, this paradigm is limited by sampling error and subtle endoscopic changes, leading to missed HGD and EAC…